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Translational relevance
Endometrial cancer stem cells are reported to drive metastasis and disease relapse and are resistant to commonly used chemotherapeutic drugs. Here, we characterise ALDH high and CD133 +ve endometrial cancer stem cells with differing levels of cancer stem cell activity and stem cell and epithelial-mesenchymal transition (EMT) gene expression. Their proportions and activity are reduced following treatment with metformin at a lower concentration than that required to affect bulk tumour cell proliferation, establishing a selective and specific effect on endometrial cancer stem cells. We demonstrate that this effect is abrogated when endometrial cancer cells are pre-treated with adipocyte conditioned media, indicating adipokine-mediated resistance to metformin. These results support future studies of metformin as an adjuvant therapy to reduce the risk of disease recurrence but should also investigate the impact of obesity on treatment response.
Introduction
Already the fourth most common cancer in women, the incidence of endometrial cancer is rising globally as a consequence of the escalating rates of obesity, to which up to 41% of endometrial cancers can be directly attributed (1) (2) (3) . Whilst the majority of women present early with postmenopausal bleeding and disease confined to the uterus, there is a marked discrepancy in fiveyear survival between those with stage I disease (95%) and those with stage IV disease (14%) (4) .The presence of obesity may also further adversely impact upon prognosis (5) . Adipose tissue appears to play a direct role in metastasis, through the release of pro-inflammatory mediators (e.g. IL-6, TNF-α) which promote cancer cell migration and invasion (6) , the infiltration of adipocytes into tumours and promotion of neo-vascularisation (7, 8) and hormonal manipulation, in particular the release of prometastatic leptin, oestrogen and insulin-like growth factor-1 (9) (10) (11) , although the relative importance of each of these pathways in endometrial carcinogenesis remains to be determined.
Treatment options for extra-uterine disease are limited, with carboplatin and paclitaxel chemotherapy frequently used despite there being no evidence to suggest that it improves overall survival (12) .Indeed, any modest short term benefit from chemotherapy is counteracted by an ongoing risk of disease relapse after treatment is discontinued (13) . This has been hypothesised to be due to the persistence of a sub-population of tumour cells referred to as cancer stem cells (14) . These progenitor stem cells have acquired the capacity for self-renewal through the accumulation of mutations in the Wnt/β-catenin, BMI1 and Hippo signalling pathways and are able to differentiate into multiple different cell types (15) (16) (17) (18) . They form tumours when transplanted into animal models at much lower concentrations than bulk tumour cells, have increased invasion and migration capacity and are resistant to commonly used chemotherapeutic drugs, making them responsible for metastasis and disease relapse (19) .
In order to study the unique characteristics of these cells in more detail, two broad means of identifying and separating these cells from the bulk tumour population are frequently employed; detection of cell surface markers and enzyme activity, and the use of functional assays. Expression of CD133, a glycosylated pentaspan membrane protein, has been shown to be restricted to undifferentiated cells, and a population of CD133 +ve cells has been described in primary endometrial tumours that demonstrate many of the characteristics of cancer stem cells, including self-renewal, multipotency and increased tumour formation in immunodeficient mice (20) (21) (22) (23) . Similar traits are exhibited by endometrial cancer cells with high activity levels of the aldehyde dehydrogenase (ALDH) enzyme, which plays a critical role in retinoic acid signalling, including increased colony and tumour forming capacity, invasive potential and resistance to the cytotoxic effects of cisplatin chemotherapy (24) (25) (26) . Despite this, the relationship between CD133 +ve and ALDH high endometrial cancer cells and their relative cancer stem cell activity is unknown. Functional assays for the determination of stem cell characterisation include the formation of three dimensional 'spheres' under non-adherent conditions, which would normally be associated with cell aniokis (27) . This technique has been well described in other tumour types but has not previously been undertaken using this standardised protocol in endometrial cancer.
Regardless of the increasing awareness of the importance of cancer stem cells in disease relapse and metastasis, there have been relatively few specific therapeutic options examined to target these cells in endometrial cancer. Limited cell line data suggests ruxolitinib and nifuroxazide (JAK1 and STAT3 inhibitors, respectively) may be of benefit, but these findings have not been replicated in humans, and whilst short-term progestin treatment appears promising, effects are seen in only a proportion of women (25, 28).
Evidence from other tumour types suggests that metformin may selectively target cancer stem cells by reducing sphere and in vivo tumour formation, for example, when tested in a mouse xenograft breast cancer model (29) . Indeed, the drug appears to act synergistically with other chemotherapeutic drugs, including platinum agents and doxycycline, and is associated with prolongation of disease remission (30, 31) . Metformin decreases the expression of cancer stem cell related genes associated with pluripotency, self-renewal and the Hippo pathway, including SOX9, β-catenin and YAP1, and appears to reduce the proportion of ALDH high ovarian cancer cells and CD133 +ve pancreatic cancer cells at a concentration that does not affect the proliferation of whole tumour cell lines (31) (32) (33) (34) (35) . Despite widespread interest in metformin in other aspects of the management of endometrial cancer, the effect of the drug on endometrial cancer stem cells has not previously been studied, although there is limited observational data to suggest that it may act as a chemosensitiser (36) (37) (38) . Whilst our own randomised controlled pre-surgical window study did not demonstrate reduced endometrial cancer cell proliferation in response to metformin exposure, as measured by immunohistochemical expression of Ki-67, this does not preclude a specific effect of the drug on endometrial cancer stem cells (39 Sphere formation and passaging
Sphere formation was performed as previously described (27) . Single cells were seeded onto low adherent plates containing stem cell media (Gibco, Paisley, UK) with or without additional metformin (0.1-20mM) and cultured for five days. The number of spheres formed were counted using a light microscope. To assess self-renewal, spheres were disaggregated and replated, with the number of secondary spheres counted after a further five days of culture.
Flow cytometry
Flow cytometry was performed using the BD LSR II flow cytometer (BD Biosciences, Oxford, UK) and analysed using FlowJo software. Cell sorting was performed using the Aria II/III flow cytometer (BD Biosciences, Oxford, UK).
CD133
Single dissociated Ishikawa and Hec-1a cells were suspended in buffer composed of 5% (v/v) bovine serum albumin (BSA), 2mM ethylenediaminetetracetic acid (EDTA) and PBS and incubated with either CD133-APC or CD133-VioBright FITC antibodies (both monoclonal mouse, Miltenyi Biotec, dilution 1:500) and FcR blocking reagent (Miltenyi Biotec, dilution 1:5) or isotype control antibody (mouse IgG1, Miltenyi Biotec, dilution 1:11) for 10 minutes in the dark at 2-8 o C. Following incubation, cells were washed and resuspended in buffer for flow cytometry.
ALDH activity
Single dissociated cells were suspended in Aldefluor assay buffer (STEMCELL technologies, Cambridge UK) and incubated with an ALDH substrate, bodipyaminoacetaldehyde (BAAA), at 1.5mM for 45 minutes at 37 o C. In order to distinguish between high and low ALDH activity, a fraction of cells were incubated under identical conditions in the presence of a two-fold molar excess of ALDH inhibitor (diethylaminobenzaldehyde, DEAB). 7-actinoaminomycin-D (7AAD) was used for dead cell exclusion.
Mitochondrial mass
Cancer stem cells in other cancer types have been characterised by high mitochondrial mass (41) . Single dissociated cells were thus incubated with 25nM Mitotracker (Fisher Scientific, Loughborough, UK) dissolved in DMSO for 45 minutes at 37 o C either at the same time as the ALDEFLUOR reagent or prior to the addition of the CD133 antibody.
Sulforhodamine B (SRB) cytotoxicity assay
Cell viability was determined using a SRB cytotoxicity assay (Sigma-Aldrich, Dorset, UK) in a 96-well plate with protein absorption measured at 450nM using a microplate photometer.
Real Time quantitative-Reverse Transcriptase-Polymerase Chain Reaction (RT-qPCR)
Experiments were conducted using unsorted Ishikawa and Hec-1a cells and sorted cancer stem cells according to CD133 expression and ALDH activity, which had been maintained in normal growth media with or without supplemental metformin. RNA extraction was performed using the RNeasy Micro Kit (Qiagen, Manchester, UK) according to the manufacturer's protocol.
Reverse transcription of 1.5ng of RNA was performed with the Reverse Transcription Mastermix (PN 100-6297, Fluidigm, San Francisco, USA). The cDNA formed was immediately pre-amplified using Taqman gene expression arrays (supplementary table S1 , Fisher Scientific, Loughborough, UK) and Taqman PreAmp Mastermix (Fisher Scientific, Loughborough, UK).
RT-qPCR was performed using the Flex Six™ Integrated Fluidic Circuit (IFC, Fluidigm, San Francisco, USA). Pre-amplified cDNA was added to a sample pre-mix composed of Taqman Fast Advanced MasterMix (2X, PN 4444557, Fisher Scientific, Loughborough, UK) and 20X GE Sample Reagent (PN 100-6311, Fluidigm, San Francisco, USA). Assays and sample solutions were pipetted into the designated IFC inlets. RT-qPCR was performed using the BiomarkHD system, with data analysed using the Biomark Real-Time PCR Analysis Software.
Immunohistochemistry
Tissue microarrays (TMAs) were constructed from endometrial tumours sampled by prior to and following treatment with metformin or placebo as part of the PREMIUM study [full study details published elsewhere (39)]. Immunohistochemistry was performed using the Leica Bond Max and Refine Detection Kit. Scoring was performed blind to treatment group using Definiens Developer software (version 2.7).
Statistical analysis
All experiments were performed in triplicate on at least three occasions and results are presented as the mean ± standard error of the mean (SEM). The student's T test or analysis of covariance was used to compare normally distributed, paired data. The effect of metformin on the immunohistochemical expression of CD133 and ALDH was determined using an analysis of covariance model, with baseline expression as a covariate. A two-sided p value ≤0.05 was considered statistically significant, with asterisk used to indicate significant results as *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. All analyses were performed using GraphPad Prism v.7 and SPSS v.23. figure 1d ), suggesting they may be more sensitive to mitochondrial inhibitors, such as metformin, than bulk tumour cells.
We determined the extent of overlap between the two populations of cells with cancer stem cell activity in the Ishikawa cell line using dual staining and flow cytometry. Double positive cells had the greatest sphere formation efficiency, with double negative cells forming the fewest number of spheres (figure 1e). ALDH activity correlated better with cancer stem cell activity than CD133. The markers identified two almost exclusive populations of cells with cancer stem cell activity, with only 0.01% of cells expressing both markers (supplementary figure S1). This was confirmed when the relative expression of epithelial and mesenchymal markers were examined in the two cell populations (figure 1f We then studied the expression of transcription factors controlling epithelial-mesenchymal transition and, hence, cancer metastasis. Expression of SNAI1 was increased in ALDH high cells in both cell lines studied, with Ishikawa ALDH high cells also demonstrating upregulation of TWIST (figure 2c). Metformin reduces the number and activity of endometrial cancer stem cells
We next sought to investigate the effect of metformin on endometrial cancer stem cell activity and number in the two cell lines. Metformin had a dose dependent effect on cancer stem cell activity, as measured by sphere formation efficiency, in both Ishikawa and Hec-1a cell lines ( figure 3a ). An effect on sphere formation efficiency was observed with as low as 0.5mM metformin, with a 1.3-fold decrease in Ishikawa SFE (p=0.03) and a 1.6-fold decrease in Hec-1a SFE (p=0.008). At a concentration of 20mM, almost no spheres were formed in either cell line.
Using the two lowest concentrations of metformin at which an effect on sphere formation efficiency was observed, the effect of the drug on the proportion of ALDH high and CD133 +ve cells was determined. Metformin, at a concentration of 1mM, significantly reduced the proportion of Hec-1a cancer stems identified by high ALDH activity by 1.7-fold (p≤0.05, figure 3b ). By contrast, the same dose of metformin had no effect on the proportion of ALDH Whilst metformin decreased the cancer stem cell activity of the two endometrial cancer cell lines, it had no effect on the self-renewal capacity of these cells (supplementary figure S3a).
The reduction in sphere formation efficiency of the Ishikawa and Hec-1a cells was indeed due to an effect of metformin on cancer stem cell activity rather than because increased cell death, as demonstrated in a SRB assay (supplementary figure S3b). A concentration of at least 1mM metformin was required to significantly reduce the viability of Ishikawa cells and whilst 0.5mM metformin resulted in cell death in a proportion of Hec-1a cells, the effect was less than that observed on sphere formation efficiency. The IC 50 values for metformin to inhibit cancer stem cell activity and viability in the Ishikawa cell lines were 1.60mM and 6.77mM, respectively, and in the Hec-1a cell line were 1.46mM and 3.72mM, respectively.
Metformin reduced the expression of cancer stem cell genes
Metformin reduced the expression of genes associated with pluripotency and self-renewal in a dose dependent manner in the Ishikawa cells, though had a less pronounced effect in the Hec-1a cells (figure 4a, supplementary figure S4a). Metformin treatment of Ishikawa cells also resulted in a significant reduction in Wnt pathway activation and Hippo signalling in a dose dependent manner (figure 4b). Hec-1a cells treated with 1mM metformin had lower CTNNB1 and YAP1 expression than controls, but an increase in WNT2 expression.
The effect of metformin on the expression of EMT transcription factors was more heterogeneous. Treatment with 1mM metformin resulted in a two-fold reduction in TWIST and SNAI1 expression (both p≤0.05) in Ishikawa cells, whilst having no significant effect in Hec-1a cells (figure 4c). In contrast, the same concentration increased the expression of ZEB1 in Ishikawa cells by 1.3-fold, but reduced expression in Hec-1a cells (fold change 0.9±0.03, p=0.05, supplementary figure S4b).
Patient-derived adipocyte conditioned media increased endometrial cancer stem cell activity but reduced the sensitivity of these cells to metformin treatment without affecting cell proliferation In order to investigate the impact of obesity on endometrial cancer cell proliferation and cancer stem cell activity, conditioned media was obtained from patient-derived adipocytes that had undergone maturation in response to exposure to adipocyte differentiation media. The baseline characteristics of the six women from whom pre-adipocytes were cultured are detailed in supplementary table S2. Pre-adipocytes treated for 15 days with differentiation media showed 100% differentiation into mature adipocytes, with a rounded morphology and positive triglyceride staining with Oil Red O. Treatment for 10 and 12 days resulted in a lesser degree of differentiation in a small proportion of cells only (figure 5a). Pre-adipocytes exposed to growth media only retained their fibroblast-like phenotype; they did not contain lipid droplets or demonstrate positive staining with Oil Red O (supplementary figure S5a).
We determined the effect of adipocyte conditioned media on endometrial cancer proliferation and response to metformin treatment using a SRB assay. Exposure to patient-derived adipocyte conditioned media did not affect the proliferation of endometrial cancer cells grown in monolayer, neither did it alter the responsiveness of these cells to treatment with metformin (figure 5b).
Treatment with pre-adipocyte conditioned media similarly had no effect on the viability of Ishikawa cells (supplementary figure S5b).
In contrast, exposure to patient-derived adipocyte conditioned media had a significant effect on the activity of endometrial cancer stem cells. A significant increase in the cancer stem cell activity of Ishikawa cells exposed to patient-derived conditioned media from four out of six adipocyte cultures was observed (figure 5c). On average, SFE was increased 3.76±0.81-fold compared with cells treated with control (unconditioned growth) media (p=0.02). An increase in cancer stem cell activity was also noted after exposure to three out of the six corresponding pre-adipocyte conditioned medias, however, the overall effect was smaller in magnitude than that observed following treatment with mature adipocyte conditioned media (supplementary figure S5c).
In addition, the normal inhibitory effect of metformin on endometrial cancer stem cell activity was lost when these cells were pre-treated with adipocyte conditioned media for 96 hours (figure 5d). Rather than metformin treatment reducing the number of spheres formed in non-adherent culture, the SFE of Ishikawa cells was unchanged if they had been previously exposed to adipocyte conditioned media. These results suggest that under these experimental conditions, adipocyte conditioned media has a selective effect on the activity of endometrial cancer stem cells and does not affect the sensitivity of bulk tumour cells to low concentrations of metformin.
In order to determine whether these in vitro findings were of relevance to patients, we compared the immunohistochemical expression of ALDH and CD133 in endometrial cancers from patients receiving metformin or a matched placebo prior to surgery within the context of the PREMIUM randomised controlled trial (39) . Pre-and post-treatment endometrial biopsies were available for 69 patients, 33 of whom received metformin for 1-5 weeks and 35 patients were given placebo. The baseline characteristics of the two groups are shown in supplementary figure S6a.
Overall, metformin treatment was not associated with a significant reduction in immunohistochemical expression of ALDH or CD133 (supplementary figure S6b). The mean difference in post-treatment ALDH and log (CD133+0.01) expression between the metformin and placebo treated groups was -1.52% (95%CI -12.59 to +9.56, p=0.79) and -0.16 (95%CI -0.97 to +0.66, p=0.71), respectively, after adjusting for baseline expression. Subgroup analysis did not suggest that baseline BMI was a significant modulator of treatment response to metformin (ALDH p=0.34, CD133 p=0.67).
Discussion
High ALDH activity and CD133 positivity identifies two almost mutually exclusive populations of cells in the two endometrial cancer cell lines, Ishikawa and Hec-1a, which have increased cancer stem cell activity, as determined by their ability to form spheres in non-adherent culture. ALDH high cells have the greater cancer stem cell activity and have increased expression of stem cell and EMTtranscription factor genes compared with CD133 +ve cells. The increased mitochondrial mass of endometrial cancer stem cells makes them more susceptible to inhibitors of mitochondrial function than bulk tumour cells. Indeed, metformin reduces the number and activity of endometrial cancer stem cells at a concentration lower than that required to affect cell proliferation. It also decreases the expression of genes associated with self-renewal, pluripotency and induction of EMT, although only in the Ishikawa cell line. Adipocyte conditioned media selectively increases cancer stem cell activity but also reduces the sensitivity of these cells to the effects of metformin, suggesting potential resistance to its anti-tumour effect in obese women.
The proportions of ALDH high and CD133 +ve cells in the two endometrial cancer cell lines reported here are similar to those in other studies (42) (43) (44) . This is the first study, however, in which the two populations of cells with cancer stem cell activity have been directly compared at a functional and genetic level. Ding et al. investigated stem cell gene expression in CD133 +ve cells, noting that they had significantly increased expression of SOX2 and NANOG as well as EPCAM (22) . This contrasts with the findings described here, where RNA expression of all stem cell and epithelial markers was significantly lower in CD133 +ve compared with CD133 -ve cells. This may be because of differences between EMT and gain of cancer stem-like cell properties has been proven, complete EMT is unusual in the majority of cancers, with most expressing both epithelial and mesenchymal markers (46, 47) . Indeed the balance between EMT and its reverse process, mesenchymal-epithelial transition, appears to be important in not only driving metastasis but also establishing new tumours at distant sites. It is, therefore, not surprising that endometrial cancer stem cells have increased expression of both epithelial and mesenchymal markers as well as the transcription factors that control this process. Low dose metformin, at least in endometrial cancer cell lines, appears to reduce the expression of SNAI1, TWIST and ZEB1 and could, therefore, influence the metastatic process, although this has yet to be proven in primary endometrial cancer samples (48) .
The effect of metformin on the number and activity of endometrial cancer stem cells is consistent with previous findings in breast, prostate and ovarian cancer, where it has been shown to decrease mammosphere formation and reduce tumour growth in xenograft models (29) (30) (31) . That this effect is at least attenuated, if not lost completely, when cells are pre-treated with adipocyte conditioned media is an important finding. Based on these results it would appear that this phenomenon is related to secreted mediators (adipokines) from mature adipocytes. Future work is needed to identify these proteins, through the use of adipokine multiplex ELISA arrays, and to develop targeted therapies against them if metformin is to be used effectively in the adjuvant setting for endometrial cancer.
An active role for adipocytes in endometrial cancer biology is becoming established. A recent study by Sahoo et al. found that adipocyte conditioned media increased the colony forming capacity of Ishikawa cells and reduced their responsiveness to paclitaxel when co-treated for 72 hours (49) . In contrast to the findings of this study and our previously published clinical trial, however, the authors also described an increase in endometrial cancer cell proliferation with adipocyte conditioned media treatment. There are notable differences in methodology between the two laboratory studies, though, including the fact that Sahoo et al. used conditioned media generated from a mouse preadipocyte cell line that had been induced to undergo differentiation rather than primary adipocytes, and that they used a cell viability assay that detected ATP production rather than the number of cells present. Adipocyte conditioned media has been shown to increase the rate of oxidative phosphorylation in ID8 ovarian cancer cells and this could thus explain the increase in ATP production rather than a true increase in cell number (50) . The SRB utilised in this study, in contrast, relies on the binding of SRB to proteins to determine cell mass and hence avoids the potential pitfalls associated with assays which measure the metabolic activity of cells (51) .
The strengths of this work include the replication of experimental results in two distinct endometrial cancer cell lines, thereby increasing the generalisability of the results obtained. The effect of metformin on both the number and function of cancer stem cells in vitro was investigated and correlated with clinical samples to determine applicability in vivo. The development of a model of obesity associated endometrial cancer also provides an opportunity to further understand the potential mechanisms through which excess adiposity drives endometrial carcinogenesis and possibly metformin resistance.
Cell lines do, however, have their limitations, including the risk of introducing genotypic and phenotypic variation through serial passaging, which can take them away from their cell of origin (52) . They also have limited intra-and inter-tumoural heterogeneity. Replication of experiments using primary endometrial cancer cells would help to negate these issues. This work focussed solely on endometrial cancer stem cells identified through high ALDH activity and CD133 expression on the basis of previously published, albeit limited, work in the stem cell field and does not exclude the presence of other populations of endometrial cancer stem cells. The 'gold standard' method of assessing cancer stem cell activity, in vivo transplantation in mouse xenograft models, was not employed in this current study, but would allow the effect of the drug on endometrial tumour growth and relapse in a more sophisticated endometrial cancer model to be investigated. The concentration of metformin at which an effect on endometrial cancer stem cell activity was observed was lower than that used in other experiments in endometrial cancer, but was several fold higher than that measured in plasma in humans or in endometrial cancer tissue (53, 54) . This may be related to the experimental conditions employed, in particular the use of high glucose containing growth media, which has been shown to alter the responsiveness of cells to metformin treatment (55) .
Whilst metformin did not reduce ALDH and CD133 levels in endometrial cancers from women participating in the pre-surgical window study, this may be a due to the fact that immunohistochemistry alone was used to determine expression. The antibodies employed recognised specific protein epitopes without, in the case of ALDH, being able to determine enzyme activity or, in the case of CD133, detecting antigens with different glycosylation sites. The trial may also have been inadequately powered to detect an effect of metformin on ALDH and CD133 expression as well as any modulating effect of BMI on treatment response as these were only exploratory outcomes.
Future clinical trials of metformin should focus on its efficacy as a potential maintenance treatment to reduce the risk of endometrial cancer recurrence. An initial step could be to undertake a presurgical window study to determine the effect of metformin on the proportion of ALDH high and CD133 +ve primary cells detected by flow cytometry as well as endometrial cancer sphere formation in women at high risk of disease relapse. It should be sufficiently powered to allow for the impact of obesity on treatment response to be determined. Confirmation of an effect could pave the way for longer term treatment with the drug for up to five years with relapse-free and overall survival as outcome measures.
Conclusion
ALDH activity and CD133 expression identify two distinct populations of endometrial cancer cells with different cancer stem cell activity and expression of stem cell and EMT genes. Metformin, at a concentration lower than that required to affect proliferation, reduces the number and activity of these cells in vitro. This effect is diminished, however, in the presence of adipocyte conditioned media. Identification of the adipokines responsible for metformin resistance should be pursued and the efficacy of long term drug treatment on endometrial cancer stem cell activity, relapse and survival should be determined in well-designed randomised controlled trials. 
